CEO Michael Farrell exercises stock options and immediately sells full position; mixed timing history raises questions amid recent stock weakness.
Michael Farrell, ResMed's Chairman and CEO, exercised stock options on the same day and immediately sold the entire position, a classic cashout pattern that reflects no conviction in the stock at current levels. The timing is notable: the stock has declined significantly from its 52-week high and is trading near its 52-week low, yet Farrell chose to exit rather than hold. His prior five sales at ResMed show mixed results—four were well-timed as the stock subsequently declined, but one saw the stock rise afterward—suggesting his sales have captured some downside but without a consistent edge. This marks his 31st open-market sale in the past three years with zero open-market purchases, indicating a long-running pattern of liquidating equity rather than accumulating it. ResMed remains profitable with growing revenue and a reasonable valuation, but the combination of near-52-week-low pricing and the CEO's immediate full exit following an option exercise suggests he saw the current level as an opportunity to monetize rather than a window to increase his stake.